The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop

Although infection by primary HIV type 1 (HIV-1) isolates normally requires the functional interaction of the viral envelope protein with both CD4 and the CCR-5 coreceptor, a subset of such isolates also are able to use the distinct CCR-3 receptor. By analyzing the ability of a series of wild-type and chimeric HIV-1 envelope proteins to mediate CCR-3-dependent infection, we have determined that CCR-3 tropism maps to the V1 and V2 variable region of envelope. Although substitution of the V1/V2 region of a CCR-3 tropic envelope into the context of a CCR-5 tropic envelope is both necessary and sufficient to confer CCR-3 tropism, this same substitution has no phenotypic effect when inserted into a CXCR-4 tropic HIV-1 envelope context. However, this latter chimera acquires both CCR-3 and CCR-5 tropism when a CCR-5 tropic V3 loop sequence also is introduced. These data demonstrate that the V1/2 region of envelope can, like the V3 loop region, encode a particular coreceptor requirement and suggest that a functional envelope:CCR-3 interaction may depend on the cooperative interaction of CCR-3 with both the V1/V2 and the V3 region of envelope.

Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection

A genetic defect in a CC-chemokine receptor (CCR)-5, the principal coreceptor for the macrophage-tropic HIV type 1 (HIV-1), recently was found to naturally protect CCR-5-defective, but healthy, individuals from HIV-1 infection. In this study, we mimic the natural resistance of the CCR-5-defective individuals by designing a strategy to phenotypically knock out CCR-5. The inactivation of the CCR-5 coreceptor is accomplished by targeting a modified CC-chemokine to the endoplasmic reticulum to block the surface expression of newly synthesized CCR-5. The lymphocytes transduced to express the intracellular chemokine, termed “intrakine,” were found to be viable and resistant to macrophage-tropic HIV-1 infection. Thus, this gene-based intrakine strategy targeted at the conserved cellular receptor for the prevention of HIV-1 entry should have significant advantages over currently described approaches for HIV-1 therapy.

Characterization of BseMII, a new type IV restriction–modification system, which recognizes the pentanucleotide sequence 5′-CTCAG(N)10/8↓

We report the properties of the new BseMII restriction and modification enzymes from Bacillus stearothermophilus Isl 15-111, which recognize the 5′-CTCAG sequence, and the nucleotide sequence of the genes encoding them. The restriction endonuclease R.BseMII makes a staggered cut at the tenth base pair downstream of the recognition sequence on the upper strand, producing a two base 3′-protruding end. Magnesium ions and S-adenosyl-l-methionine (AdoMet) are required for cleavage. S-adenosylhomocysteine and sinefungin can replace AdoMet in the cleavage reaction. The BseMII methyltransferase modifies unique adenine residues in both strands of the target sequence 5′-CTCAG-3′/5′-CTGAG-3′. Monomeric R.BseMII in addition to endonucleolytic activity also possesses methyltransferase activity that modifies the A base only within the 5′-CTCAG strand of the target duplex. The deduced amino acid sequence of the restriction endonuclease contains conserved motifs of DNA N6-adenine methylases involved in S-adenosyl-l-methionine binding and catalysis. According to its structure and enzymatic properties, R.BseMII may be regarded as a representative of the type IV restriction endonucleases.

The experimental stress analysis of the Firestone type R-5⁰, 20 x 75 truck rim.

Vols. 2-3 have title: The experimental stress analysis of truck rims.

Specifications for bituminous surface, open-graded aggregate type, subclass C-5 (Machine mix-emulsified asphalt) : effective July 1, 1945.

Reproduced from typewritten copy.

Unit, direct support, and general support maintenance repair parts and special tools lists : drill, pneumatic, drifter, boom-type, crawler-mounted, self-propelled (NSN 3820-00-445-3766), Joy model RAM-MS-5/450A-DR.

"May 1992."

Unit maintenance repair parts and special tools lists : loader, scoop type, DED, 4 x 4, articulated frame steer, 4 1/2 to 5 cu. yd., (CCE), Army model H100C RB, type I with 4 1/2 cu. yd. rock bucket, NSN 3805-01-052-9042, Army model H100C GPB, type II with 5 cu. yd. general purpose bucket, NSN 3805-01-052-9043.

Includes indexes.

Unit maintenance repair parts and special tools list : loader, scoop type, DED 4 x 4, articulated frame steer, 4 1/2 to 5 cu. yd., (CCE), with 4 1/2 cu. yd. rock bucket, NSN 3805-00-602-5006, Clark model 175B, type I and with 5 cu. yd. general purpose bucket, NSN 3805-00-602-5013 Clark model 175B, type II.

Includes indexes.

Intermediate direct support and intermediate general support maintenance repair parts and special tools lists ... : loader, scoop type, DED, 4 x 4, articulated, frame steer, 4 1/2 to 5 cu. yd., (CCE), Army model H100C RB, type I with 4 1/2 cu. yd. rock bucket ....

"October 1988."

Organizational, direct support and general support maintenance repair parts and special tools lists : drill, pneumatic, drifter, boom-type, crawler-mounted, self-propelled NSN 3820-00-445-3766, Joy model RAM-MS-5/450A-DR.

Includes indexes.

Operator, organizational, direct support, general support, and depot maintenance manual : theodolite, directional, 0.2 mil graduation, 5.9 in. long telescope, w/accessories (Wild Heerbrugg models), (model T16-mil 66, type II), FSN 6675-926-4505 (model T16-mil 68, type II), FSN 6675-861-7939, theodolite, directional, 1 min graduation, 5.9 in. long telescope, w/accessories ....

"March 1970."

Direct and general support and depot maintenance, repair parts and special tools lists : theodolite, directional, 1 min. graduation, 5.9-in. long telescope w/accessories, (Wild Heerbrugg model T-16 type l) FSN 6675-828-6397.

Includes index.

Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities

In humans, a polymorphic gene encodes the drug-metabolizing enzyme NATI (arylamine N-acetyltransferase Type 1), which is widely expressed throughout the body. While the protein-coding region of NATI is contained within a single exon, examination of the human EST (expressed sequence tag) database at the NCBI revealed the presence of nine separate exons, eight of which were located in the 5'non-coding region of NATI. Differential splicing produced at least eight unique mRNA isoforms that could be grouped according to the location of the first exon, which suggested that NATI expression occurs from three alternative promoters. Using RT (reverse transcriptase)-PCR, we identified one major transcript in various epithelial cells derived from different tissues. In contrast, multiple transcripts were observed in blood-derived cell lines (CEM, THP-1 and Jurkat), with a novel variant, not identified in the EST database, found in CEM cells only. The major splice variant increased gene expression 9-11-fold in a luciferase reporter assay, while the other isoforrns were similar or slightly greater than the control. We examined the upstream region of the most active splice variant in a promoter-reporter assay, and isolated a 257 bp sequence that produced maximal promoter activity. This sequence lacked a TATA box, but contained a consensus Sp1 site and a CAAT box, as well as several other putative transcription-factor-binding sites. Cell-specific expression of the different NATI transcripts may contribute to the variation in NATI activity in vivo.

Caractérisation des inhibiteurs de DCIR, une lectine de type C participant à la transmission du VIH-1

Le virus de l’immunodéficience humaine de type 1 provoque une infection définitive de l’organisme. Il entraine une déroute du système immunitaire depuis la primo-infection occasionnant ainsi, une déplétion massive des lymphocytes T CD4 (LTCD4). Le DCIR (Dendritic Cell Immuno Receptor) qui constitue le socle de notre travail, est une lectine de type C. Il est exprimé sur les cellules myéloïdes comme les cellules dendritiques mais aussi sur les cellules B, les LTCD4 infectés par le VIH-1 et apoptotiques ainsi que sur les LTCD4 polarisés en Th17. Il constitue un facteur d’attachement et d’internalisation du virus dans la cellule dendritique. Il permet son transfert aux LTCD4 dans les organes lymphoïdes secondaires, jouant ainsi un rôle dans la pathogenèse associée au VIH-1. En plus, le DCIR assure la régulation négative de la réponse cellulaire, favorisant ainsi la propagation et la réplication du virus au détriment de la réponse immunitaire contre le VIH-1. Le rôle que joue le DCIR est dépendant du sentier de signalisation induit à la suite de la phosphorylation des résidus tyrosine de son motif ITIM. Le blocage de DCIR par des inhibiteurs spécifiques pourrait empêcher cette phosphorylation et réduire l’attachement, l’internalisation et le transfert du virus. Nous avons montré que la stimulation des cellules dendritiques et des LTCD4 polarisés en Th17 avec un anticorps anti-DCIR générait un patron de phosphorylation des résidus tyrosine des protéines. De plus, les inhibiteurs de la portion extracellulaire du DCIR inhibent cette activation. Afin de développer une mesure plus directe de l’interaction de DCIR avec ces inhibiteurs, nous avons purifié le DCIR à partir des cellules Raji-CD4-DCIR. En conclusion, ce projet de maitrise montre que l’activation directe de DCIR peut être renversée par des inhibiteurs montrant ainsi leurs spécificités. De plus, le profil d’activation de DCIR est spécifique pour chaque type cellulaire. A long terme, l’inactivation de DCIR par des inhibiteurs efficaces pourrait être une stratégie thérapeutique capable d’inhiber l’infection et de préserver une réponse immunitaire efficace.